ArticleActa pharmaceutica Sinica. B2024
Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor.
Kai Tang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it